671 related articles for article (PubMed ID: 27683115)
21. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
23. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
25. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
26. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
28. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic implications of CD8
Zou MX; Guo KM; Lv GH; Huang W; Li J; Wang XB; Jiang Y; She XL
Cancer Immunol Immunother; 2018 Feb; 67(2):209-224. PubMed ID: 29051990
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
32. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
33. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
34. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
35. Programmed death ligand 1 expression and CD8
Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
40. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]